Affymetrix Bets Branched DNA Will Drive Growth in Expression Market | GenomeWeb

By Justin Petrone

Affymetrix is betting that its branched DNA-based QuantiGene kits, on board since its 2008 acquisition of Panomics, will spur growth in the gene-expression market and eventually challenge RT-PCR, according to a company official.

"More and more of our expression products are being used downstream," according to Doug Farrell, head of investor relations. "We see more use in validating biomarkers, clinical trials; things of that nature."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.